ABI
QGENF

Adamant Biomedical Investments’s QIAGEN NV QGENF Stock Holding History

Adamant Biomedical Investments’s Portfolio QGENF Stock Details QGENF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$2.34M Sell
100,000
-150,610
-60% -$3.53M 0.56% 58
2014
Q3 		$5.19M Buy
+250,610
New +$5.19M 1.3% 27

Other funds holding QGENF

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CRM
Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return

Adamant Biomedical Investments's QGENF Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its QIAGEN NV (QGENF) stake by 60% in Q4 2014, selling an estimated $3.53M and leaving 100,000 shares worth $2.34M. The position accounts for 0.56% of the portfolio, ranked #58.

Adamant Biomedical Investments first reported a position in QGENF in Q3 2014 and has held it in 2 quarters since. The position peaked at $5.19M in Q3 2014. 172 funds tracked by Wall St. Rank hold QGENF as of Q4 2014.

  • Adamant Biomedical Investments held 100,000 shares of QIAGEN NV worth $2.34M as of Q4 2014.
  • Adamant Biomedical Investments sold 150,610 QIAGEN NV shares in Q4 2014, an estimated $3.53M.
  • QIAGEN NV made up 0.56% of Adamant Biomedical Investments's portfolio in Q4 2014, its #58 holding.
  • Adamant Biomedical Investments first reported a position in QIAGEN NV in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's QIAGEN NV position peaked at $5.19M in Q3 2014.
  • 172 funds tracked by Wall St. Rank held QIAGEN NV as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.